Get the Stockscreener App
0.645
2.71%
-0.018
After Hours:
.63
-0.015
-2.33%
Oragenics Inc stock is traded at $0.645, with a volume of 61,288.
It is down -2.71% in the last 24 hours and down -24.98% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.663
Open:
$0.66
24h Volume:
61,288
Relative Volume:
0.19
Market Cap:
$2.69M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.0755
EPS:
-8.54
Net Cash Flow:
$-8.25M
1W Performance:
-0.72%
1M Performance:
-24.98%
6M Performance:
-44.87%
1Y Performance:
-92.69%
1-Day Range:
$0.6111
$0.6682
1-Week Range:
$0.6111
$0.7648
52-Week Range:
$0.6111
$9.60
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.645 | 2.76M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Oragenics Inc Stock (OGEN) Latest News
Oragenics previews targeted milestones for 2026 - Yahoo Finance
Oragenics (OGEN) Progresses ONP-002 for Potential $9 Billion Con - GuruFocus
Oragenics Targets Projected $9 Billion Market by Advancing - GlobeNewswire
Portfolio Shifts: What is the next catalyst for Oragenics IncJuly 2025 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Oragenics partners with Duck Flats Pharma to support FDA IND trial design - Yahoo Finance
Oragenics (OGEN) Partners with Duck Flats Pharma for U.S. IND Re - GuruFocus
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - Sahm
Oragenics Advances Concussion Treatment Development with SCOPE Summit Participation Ahead of Australian Phase 2a Trial - citybuzz -
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care - GlobeNewswire
Investor Mood: Is Oragenics Inc stock technically oversold2025 Risk Factors & Growth Focused Stock Reports - baoquankhu1.vn
Market Trends: Is now the right time to enter LPLAWeekly Trade Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Rate Hike: What is the next catalyst for Oragenics IncQuarterly Portfolio Summary & Verified Entry Point Detection - baoquankhu1.vn
Oragenics Extends At-the-Market Equity Sales Agreement - The Globe and Mail
Oragenics amends at-the-market sales agreement with Dawson James Securities By Investing.com - Investing.com Australia
Oragenics amends at-the-market sales agreement with Dawson James Securities - Investing.com
Oragenics Signs Amendment to At-the-Market Sales Agreement With Dawson James Securities - TradingView
Telling Fred sells Oragenics (OGEN) shares for $198 By Investing.com - Investing.com Nigeria
Telling Fred sells Oragenics (OGEN) shares for $198 - Investing.com
Sell Signal: What is the target price for Oragenics Inc stockJuly 2025 Short Interest & Fast Moving Trade Plans - baoquankhu1.vn
Aug Chart Watch: What is the next catalyst for Oragenics IncWeekly Earnings Recap & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Oragenics (NYSEAMERICAN:OGEN) Shares Up 1.9% – Should You Buy? - Defense World
Oragenics to Showcase Concussion Treatment Progress at Investor Summit - citybuzz -
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico - marketscreener.com
OGENOragenics Latest Stock News & Market Updates - Stock Titan
Will Oragenics Inc. stock sustain bullish trend into 2025Portfolio Risk Report & Reliable Intraday Trade Plans - Улправда
Why Oragenics Inc. stock is favored by top institutionsMarket Trend Report & Fast Entry and Exit Trade Plans - Улправда
Can Oragenics Inc. stock deliver surprise earnings beatEarnings Growth Summary & Stepwise Entry and Exit Trade Signals - Улправда
Can Oragenics Inc. stock beat market expectations this quarter2025 Winners & Losers & Community Consensus Trade Alerts - Улправда
Investment Recap: Is Oragenics Inc stock attractive after correctionJuly 2025 News Drivers & Reliable Momentum Entry Alerts - Bộ Nội Vụ
Published on: 2026-01-07 07:41:25 - moha.gov.vn
Why analysts upgrade Oragenics Inc. stock2026 world cup usa national team quarterfinals defensive leaders set piece tactics tactical prediction analysis - Улправда
Is Oragenics Inc. stock vulnerable to rate hikesStock Market Trends & Outstanding Investment Returns - bollywoodhelpline.com
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Common Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Convertible Preferred Stock. of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - MarketScreener
Is Oragenics Inc. stock ideal for retirement investorsJuly 2025 Outlook & High Return Stock Watch Alerts - Улправда
Aug Patterns: Why analysts upgrade Oragenics Inc. stockDollar Strength & Weekly Market Pulse Updates - Улправда
Growth Review: Can Oragenics Inc. stock beat market expectations this quarterJuly 2025 Trends & Free Community Consensus Stock Picks - moha.gov.vn
Momentum Shift: Is Oragenics Inc. stock resilient to inflationJuly 2025 Market Mood & Fast Gain Stock Tips - Улправда
Will Oragenics Inc. stock deliver shareholder valueWeekly Profit Report & High Return Trade Opportunity Guides - Улправда
Is Oragenics Inc. stock resilient to inflationJuly 2025 Summary & Verified Short-Term Plans - Улправда
Can Oragenics Inc. stock sustain revenue growthWeekly Market Report & Weekly Chart Analysis and Guides - DonanımHaber
Will Oragenics Inc. stock reach all time highs in 2025Market Growth Summary & Daily Volume Surge Trade Alerts - Улправда
Is Oragenics Inc. stock trading at a premium valuationJuly 2025 Levels & Weekly High Potential Stock Alerts - Улправда
Aug Reactions: Is Oragenics Inc. stock trading at a premium valuationWeekly Trend Summary & Daily Chart Pattern Signal Reports - Улправда
Nasdaq Moves: Is Oragenics Inc. stock ideal for retirement investorsJuly 2025 Volume & Verified Technical Signals - Улправда
Earnings Miss: Will Oragenics Inc. stock reach all time highs in 2025 - Улправда
Oragenics (OGEN) CEO/CFO receives 250,000 stock options at $0.93 - Stock Titan
Oragenics (OGEN) reports immediate-vesting stock option grants to director - Stock Titan
Oragenics Adjusts Executive Compensation Plan - TipRanks
[Form 4] ORAGENICS INC Insider Trading Activity - Stock Titan
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):